Review



pegfr  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pegfr
    Pegfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1362 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+tyr1068/Phospho-EGF+Receptor+(Tyr1068)+XP+Rabbit+mAb/pm41735305-202-17-18
    Average 96 stars, based on 1362 article reviews
    pegfr - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
    Article Snippet: Birgit Wilding1*, Lydia Woelflingseder1, Anke Baum1, Krzysztof Chylinski1, Gintautas Vainorius1, Neil Gibson2, Irene C. Waizenegger1, Daniel Gerlach1, Martin Augsten1, Fiona Spreitzer1, Yukina Shirai3, Masachika Ikegami3, Sylvia Tilandyová1, Dirk Scharn1, Mark A. Pearson1, Johannes Popow1, Anna C. Obenauf4, Noboru Yamamoto5, Shunsuke Kondo5, Frans L. Opdam6, Annemarie Bruining7, Shinji Kohsaka3, Norbert Kraut1, John V. Heymach8, Flavio Solca1, and Ralph A. Neumüller1* D ow nloaded from http://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.C D -24-0306/3506366/cd-24-0306.pdf by guest on 13 N ovem ber 2024 AACRJournals.orgOF2 | CANCER DISCOVERY XXX 2024 1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.. 2Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.. 3Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.

    Article Title: FGF receptor kinase inhibitors exhibit broad antiviral activity by targeting Src family kinases
    Article Snippet: The following primary antibodies were used: pLyn Tyr397 (Invitrogen; MA5-38270; 1:1000 diluted), total Lyn (Invitrogen; MA5-14924; 1:1000 diluted), Annexin A2 (Invitrogen; PA5-27085; 1:1000 diluted); pAnnexin A2 Tyr24 (Invitrogen; PA5-105372; 1:1000 diluted), vinculin (Sigma-Aldrich; v4505; 1:500 diluted), phospho-p42/44 ERK1(2 (Cell Signaling, Danvers, MA; 9101; 1:1000 diluted), total ERK1/2 (Cell Signaling; 9102; 1:1000 diluted), phospho-p38 (Cell Signaling; 9211 S; 1:1000 diluted), total p38 (Cell Signaling; 9212 S; 1:1000 diluted), GAPDH (HyTest, Turku, Finland; 5G4; 1:1000 diluted), α-tubulin (Sigma Aldrich, T5168, 1:5000 diluted), histone H3 (Abcam, Cambridge, UK; ab1791; 1:2000 diluted), total EGFR (Cell Signaling; 373746: 1:1000 diluted), pEGFR-Tyr1068 (Cell Signaling; 3777; 1:1000 diluted), and HSV-1 glycoprotein D (Abcam, ab18638, diluted 1:5000).

    Article Title: Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
    Article Snippet: pEGFR (Tyr1068) , Cell Signaling Technology , Cat# 2234; RRID: AB_331701.

    Article Title: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
    Article Snippet: The following antibodies were used: HER2 (1:100, Cell Signaling Technology, 4290), pHER2-Tyr1196 (1:100, Cell Signaling Technology, 6942), EGFR (1:100, Cell Signaling Technology, 4267), pEGFR- Tyr1068 (1:100, Cell Signaling Technology, 3777), ERK 1/2 (1:100, Cell Signaling Technology, 9102), pERK 1/2 -Thr202/Tyr204 (1:100, Cell Signaling Technology, 4370), AKT (1:100, Cell Signaling Technology, 9272), pAKT–Ser473 (1:100, Cell Signaling Technology, 4060), DUSP6 (1:100, Abcam, ab76310), S6 (1:100, Cell Signaling Technology, 2217), pS6 –Ser235/236 (1:100, Cell Signaling Technology, 2211), and GAPDH (1:300, Abcam, ab9485).

    Article Title: TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2 + breast cancer.
    Article Snippet: Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is correlated with poor prognosis, the current treatment of which is still based on surgery and adjuvant targeted therapy with monoclonal antibody.. Problems of drug resistance hinder the use of monoclonal antibodies.. Subsequently, tyrosine kinase inhibitors (TKIs) have been noticed, TKIs have the advantages of multi-targets and reduced drug resistance.

    Western Blot:

    Article Title: Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.
    Article Snippet: Cabozantinib, mainly targeting cMet and vascular endothelial growth factor receptor 2, is the secondline treatment for patients with advanced hepatocellular carcinoma (HCC).. However, the lower response rate and resistance limit its enduring clinical benefit.. In this study, we found that cMet-low HCC cells showed primary resistance to cMet inhibitors, and the combination of cabozantinib and mammalian target of rapamycin (mTOR) inhibitor, rapamycin, exhibited a synergistic inhibitory effect on the in vitro cell proliferation and in vivo tumor growth of these cells.

    Article Title: The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes.
    Article Snippet: .. Primary antibodies used for immunoblotting: b-Actin 1:1000 (Cell Signaling Technology, 4970), USP9X 1:500 (Proteintech, 55054-1-AP), RIT1 1:1000 (Abcam, Ab53720), Vinculin 1:1500 (Sigma-Aldrich, V9264), Cyclophilin A 1:1000 (Bio-Rad, VMA00535), Cas9 1:1000 (Cell Signaling Technology, 14697), CDC20 1:2000 (Santa Cruz, 13162), Tubulin 1:2000 (Sigma-Aldrich, T5168), Flag 1:2000 (Sigma-Aldrich, F1804), HA 1:2000 (Biolegend, 901503), MCL1 1:1000 (Cell Signaling Technology, 94296), EGFR 1:1000 (Cell Signaling Technology, 2232), pEGFR tyr1068 1:1000 (Cell Signaling Technology, 2236), KRAS 1:500 (Sigma-Aldrich, WH0003845M1), pAKT ser473 1:1000 (Cell Signaling Technology 9271), MYC 1:1000 (Cell Signaling Technology 2272). .. PC9-Cas9 cells (Parental, RIT1M90I, RIT1M90I + sgUSP9X, and RIT1M90I + sgRIT1) were seeded in triplicate in 6-well tissue culture-treated dishes (CytoOne) at a density of 1x105 cells per well.

    Article Title: The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes
    Article Snippet: .. Primary antibodies used for immunoblotting: β-Actin 1:1000 (Cell Signaling Technology, 4970), USP9X 1:500 (Proteintech, 55054-1-AP), RIT1 1:1000 (Abcam, Ab53720), Vinculin 1:1500 (Sigma-Aldrich, V9264), Cyclophilin A 1:1000 (Bio-Rad, VMA00535), Cas9 1:1000 (Cell Signaling Technology, 14697), CDC20 1:2000 (Santa Cruz, 13162), Tubulin 1:2000 (Sigma-Aldrich, T5168), Flag 1:2000 (Sigma-Aldrich, F1804), HA 1:2000 (Biolegend, 901503), MCL1 1:1000 (Cell Signaling Technology, 94296), EGFR 1:1000 (Cell Signaling Technology, 2232), pEGFR tyr1068 1:1000 (Cell Signaling Technology, 2236), KRAS 1:500 (Sigma-Aldrich, WH0003845M1), pAKT ser473 1:1000 (Cell Signaling Technology 9271), MYC 1:1000 (Cell Signaling Technology 2272). .. PC9-Cas9 cells (Parental, RIT1 M90I , RIT1 M90I + sg USP9X , and RIT1 M90I + sg RIT1 ) were seeded in triplicate in 6-well tissue culture-treated dishes (CytoOne) at a density of 1x10 5 cells per well.



    Similar Products

    pegfr  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pegfr
    Pegfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+tyr1068/Phospho-EGF+Receptor+(Tyr1068)+XP+Rabbit+mAb/pm41735305-202-17-18
    Average 96 stars, based on 1 article reviews
    pegfr - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    anti pegfr  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti pegfr
    Anti Pegfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+tyr1068/Phospho-EGF+Receptor+(Tyr1068)+XP+Rabbit+mAb/pmc12892894-247-9-6
    Average 96 stars, based on 1 article reviews
    anti pegfr - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    pegfr y1068  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pegfr y1068
    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR <t>Y1068)</t> on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).
    Pegfr Y1068, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pegfr+tyr1068/Phospho-EGF+Receptor+(Tyr1068)+XP+Rabbit+mAb/bio_rxiv__64898__2025__12__19__695123-33-27-30
    Average 96 stars, based on 1 article reviews
    pegfr y1068 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).

    Journal: bioRxiv

    Article Title: EGFR/TBK1-dependent mitochondrial quality control contributes to acquired resistance to temozolomide

    doi: 10.64898/2025.12.19.695123

    Figure Lengend Snippet: A. U251 cells were treated by TMZ. Cells were harvested, fixed and stained by pTBK1 antibody coupled to fluorescent secondary antibody. pTBK1 specific fluorescence was detected by flow cytometry and expressed as a ratio to D0 fluorescence (*: p<0.05 vs D0). B. EGFR phosphorylation was measured by flow cytometry by the use of phospho-specific antibodies (pEGFR Y845 or pEGFR Y1068) on U251 or U251 Rho0 cells. Fluorescence was normalized to the fluorescence measured at D0 (*: p<0.05, **: p<0.01). C. EGFR Y845 as measured as in B. in the presence or absence of NAC 5mM (*: p<0.05, **: p<0.01). D. Phosphorylation of EGFR (Y845 and Y1068) and TBK1 was measured as in B in the presence or absence of PP1 (Src inhibitor). E. Src and TBK1 phosphorylation was measured as in B in U251 and U251 EGFR-cells treated by TMZ for the time indicated on the graph (*: p<0.05, **: p<0.01, ***: p<0.001). F. U251 and U251 EGFR-cells were treated by TMZ 50µM twice a week and cells were counted by flow cytometry at each time point. Cell number was normalized by the cell count at D0. G. The sensitivity of U251 cells to erlotinib was evaluated by MTT during TMZ treatment and the IC50 was calculated by AAT Bioquest “IC50 Calculator” tool ( https://www.aatbio.com/tools/ic50-calculator ).

    Article Snippet: TOM20 #612278, BD (Le Pont de Claix, France); TFAM #8076, Cell Signaling Technology (Danvers, MA, USA); EGFR #4267, Cell Signaling Technology; pEGFR Y845 #6963, Cell Signaling Technology; pEGFR Y1068 #3777, Cell Signaling Technology; TBK1 #3504, Cell Signaling Technology; pTBK1 #5483, Cell Signaling Technology; pSrc #sc-81521, Santa Cruz Biotechnology (Dallas, TX, France); VDAC #ab14734 Abcam, (Cambridge, UK); IP3R #sc-28614, Santa Cruz Biotechnology; LC3 #83506, Cell Signaling Technology or #L7543, Sigma Aldrich.

    Techniques: Staining, Fluorescence, Flow Cytometry, Phospho-proteomics, Cell Counting